BGI Genomics Monthly Spotlight - February 2024
BGI Genomics
BGI Genomics, based in China, is the world’s leading provider of genetic tests and sequencing services.
BGI Genomics NIFTY? DNBSEQ-G99 Platform Achieves CE-IVDD Certification - Enhancing Prenatal Care Options
Apart from our non-invasive prenatal testing kit?NIFTY? and software CE-IVDD List B, DNBSEQ-G99 has also been accredited CE-IVDD, demonstrating our dedication to complying with EU medical device laws and improving health outcomes.
Join us at the Obstetric and Perinatal Aspects in Somatic Pathology event in Uzbekistan
Dedicated to the memory of Professor A.A. Kadyrova, the conference aims to improve the quality of antenatal care for somatic pathology in primary care and obstetric institutions and to restore the reproductive function of women suffering from various diseases.
BGI Genomics Australia Team at Pathology Update 2024
Mark your calendars! BGI Genomics?Australia Team w/?Albert Hsing?will attend Pathology Update 2024, happening from 1-3 March in Adelaide. Explore our comprehensive clinical services, featuring the latest in?NIPT,?Carrier Screening, and Newborn Genetic Screening.
BGI Genomics at Lorne Genome 2024
Exciting times for BGI Genomics at Lorne Genome 2024. Albert Hsing?and our Australian team colleagues highlighted?BGI Genomics commitment to advancing healthcare through services like Xome, SENTIS?, NIFTY? Test and also held a session to illustrate the potential of low-pass whole genome sequencing during pregnancies.
World Cancer Day 2024: Close the Care Gap through Awareness, Early Detection, and Universal Access
Embrace universal?Cancer Awareness for early detection and better patient outcomes. Insights from BGI Genomics Senior Product Manager Zhang Lin and President of Fadia Survive and Thrive International Cancer Association?Rania Azmi, Ph.D.?highlight the importance of unified?efforts to step closer to a?world free from cancer's grip.